Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

COLORADO SPRINGS, Colo., Sept. 26 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced it has enrolled the first patient in the PATENT trial utilizing the Company's TURBO elite(TM) laser catheters in combination with the recently FDA cleared TURBO-Booster(TM).

The PATENT trial is a prospective registry of 100 patients at up to 10 sites in Germany. The trial will assess patency as measured by duplex ultrasound at various intervals up to 12 months following the procedure. It will also assess safety as measured by adverse events up to 12 months following the procedure. In the initial procedure performed at the Leipzig Heart Center, four focal lesions were treated successfully with the TURBO-Booster and TURBO elite 2.0mm catheter in a 20cm long stented superficial femoral artery.

"The initial result from this Spectranetics device looks very promising, as the new features allow for ablation of more tissue in larger vessels," said Andrej Schmidt, M.D., of the University of Leipzig-Heart Center. "Instent restenosis in a superficial femoral artery represents one of the most challenging procedures in our practice. The current standard of care, such as repeat balloon angioplasty, does not have good results as these lesions tend to reoccur. We are very excited with the start of this study in Germany, and we look forward to examining the mid- and long-term results of this new therapy."

John G. Schulte, Spectranetics' President and Chief Executive Officer, commented, "We are very pleased to have begun this trial at one of Europe's most prestigious medical centers. We believe that instent restenosis in the superficial femoral artery may represent 25% to 35% of all above-the-knee proce
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)...  Intec Pharma Ltd. (the "Company") (NASDAQ: NTEC ... drugs based on its proprietary Accordion Pill platform technology, ... in the United States of ... the public of $6.00 per ordinary share, before underwriting ... being offered by the Company.  In addition, the Company ...
(Date:8/4/2015)... , Aug. 4, 2015 Concord Medical Services ... leading specialty hospital management solution provider and operator of the ... China , today announced it will release its ... market closes on August 17, 2015. Management will ... day, at 8:00 a.m. EDT on August 18, 2015 (8:00 ...
(Date:8/4/2015)... 4, 2015 BioElectronics Corporation (OTC Pink: ... Pain Therapy medical devices, announced today that its ... 7-day trial device has been published in the ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic ... an assessment.  Chronic pain is ...
Breaking Medicine Technology:Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2
... International, Inc. (Nasdaq: HTWR ; ASX: HIN), ... technologies that are revolutionizing the treatment of advanced heart ... to make an investor presentation at the UBS 2010 ... 12:30 pm EDT.  The conference will be held September ...
... KING OF PRUSSIA, Pa., Sept. 15 ... into a strategic alliance with Campbell Informatics, an integrated ... alliance of Tunnell, a leading life sciences industry consultancy, ... life sciences manufacturers, suppliers and regulators, is designed to ...
Cached Medicine Technology:HeartWare to Present at the UBS 2010 Global Life Sciences Conference 2Tunnell Consulting Forms Strategic Alliance With Ireland-Based Campbell Informatics 2
(Date:8/4/2015)... ... August 04, 2015 , ... Exsurco Medical, ... of Tissue Banks (AATB) as an Affiliate Member. Exsurco Medical finds this ... to save and improve lives by promoting the safety, quality and availability of ...
(Date:8/4/2015)... Raton, FL (PRWEB) , ... August 04, 2015 ... ... diagnostic testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced ... but has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a ...
(Date:8/4/2015)... ... 04, 2015 , ... Angelina Jolie is in it at age 39. “It” ... Dr. Angela DeRosa, DO, MBA, CPE aka “Dr. Hot Flash,” arguably the ... out of menopause. , Myth #1: Menopause only affects old ladies. – Menopause ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... ... Rise of Local Food,” scheduled for Nov. 3 – 4, 2015, at UC ... food sustainably, create new businesses, improve food access, and manage resources efficiently against ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... 24/7 ... County, Los Angeles, Riverside, and San Bernardino, today announced that the U.S. Department of ... indicate that 24/7 Care At Home’s agency is well on the path to meeting ...
Breaking Medicine News(10 mins):Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3
... Md., Nov. 6 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... commercializing novel anti-infective products, today,announced that three patents ... the FDA Orange Book on,Oct. 24, 2008, pursuant ... which was,enacted on Oct. 8, 2008., MiddleBrook ...
... Nektar,Therapeutics (Nasdaq: NKTR ) today announced that it ... debt for approximately 48,cents on the dollar, for a ... its financial results for the third quarter and,nine-months ended ... now largely complete," said Nektar,President and CEO Howard W. ...
... Sysmex further expands the value and capabilities ... 6 Sysmex America, Inc. (SAI), a,leading ... today announced the launch of e-Verify(TM), the ... said,John Kershaw, President, Sysmex America, Inc. e-Verify ...
... effects on vitality unclear, scientists say , , THURSDAY, Nov. ... restore the amounts of muscle-linked growth hormone in seniors ... on the therapy also gained muscle mass over the ... that this led to significant improvements in their strength ...
... Ad Campaign Calling for "Health Reform We Can Believe In" ... ... president of Partnership for Prevention said today that President-elect Obama,s call ... health promotion a cornerstone of any health reform effort. Accordingly, the ...
... Third quarter revenues increase 65 percent versus third quarter last ... Conference Call at 4:30 p.m. Eastern Time Today, ... ), the worldwide leader in intravascular temperature,management (IVTM(TM)) therapies for ... progress for the third quarter and,nine months ended September 30, ...
Cached Medicine News:Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 2Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 3Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 4Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 2Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 3Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 4Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 5Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 6Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 7Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 8Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 9Health News:Sysmex America to Release e-Verify(TM), Powered By SNCS(TM) 2Health News:Drug Boosts Natural Growth Hormone in Seniors 2Health News:Drug Boosts Natural Growth Hormone in Seniors 3Health News:Drug Boosts Natural Growth Hormone in Seniors 4Health News:Obama's Call for "Change We Can Believe In" Makes Prevention a Priority in Health Reform 2Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 2Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 3Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 5Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 6Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 7
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With tubular base • unit ...
... Durable ergonomic chairs with concave seats ... Select options like seats, backrests, armrests, and ... Series for top performance in a variety ... room, static control, health care and office. ...
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: